UGT1A1 gene polymorphism as a potential factor inducing iron overload in the pathogenesis of type 1 hereditary hemochromatosis

Hepatology Research

Volumn 39, Issue 5, 2009, Pages 469-478

  Romanowski, Tomasz ^a   Sikorska, Katarzyna ^b   Bielawski, Krzysztof Piotr ^a  

^a UNIVERSITY OF GDA SK   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Bilirubin; Hemochromatosis; HFE; Inflammation; Iron; UGT1A1

Indexed keywords

FERRITIN; GLUCURONOSYLTRANSFERASE 1A1; HEMOGLOBIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; FERRITIN BLOOD LEVEL; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HEMOCHROMATOSIS; HEMOGLOBIN BLOOD LEVEL; HETEROZYGOTE; HUMAN; IRON BLOOD LEVEL; IRON OVERLOAD; MALE; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

EID: 65449158415     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00487.x     Document Type: Article

References (61)

1. Edwards CQ, Griffen LM, Goldgar D, Drummond C, Skolnick MH, Kushner JP. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988; 318: 1355-62.
2. Baer DM, Simons JL, Staples RL, Rumore GJ, Morton CJ. Hemochromatosis screening in asymptomatic ambulatory men 30 years of age and older. Am J Med 1995; 98: 464-8.
3. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997; 34: 275-8.
4. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999; 341: 718-24.
5. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399-408.
6. Hanson EH, Imperatore G, Burke W. HFE gene and hereditary hemochromatosis: A HuGE review. Human Genome Epidemiology. Am J Epidemiol 2001; 154: 193-206.
7. Pigeon C, Ilyin G, Courselaud B, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001; 276: 7811-19.
8. Bridle KR, Frazer DM, Wilkins SJ, et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet 2003; 361: 669-73.
9. Bradley LA, Haddow JE, Palomaki GE. Population screening for haemochromatosis: A unifying analysis of published intervention trials. J Med Screen 1996; 3: 178-84.
10. Merryweather-Clarke AT, Cadet E, Bomford A, et al. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Hum Mol Genet 2003; 12: 2241-7.
11. Jacolot S, Le GG, Scotet V, Quere I, Mura C, Ferec C. HAMP as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype. Blood 2004; 103: 2835-40.
12. Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005; 352: 1769-78.
13. Bridle K, Cheung TK, Murphy T, et al. Hepcidin is down-regulated in alcoholic liver injury: Implications for the pathogenesis of alcoholic liver disease. Alcohol Clin Exp Res 2006; 30: 106-12.
14. van der A DL, Peeters PH, Grobbee DE, Roest M, Voorbij HA, van der Schouw YT. HFE genotypes and dietary heme iron: No evidence of strong gene-nutrient interaction on serum ferritin concentrations in middle-aged women. Nutr Metab Cardiovasc Dis 2006; 16: 60-8.
15. Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut 2007; 56: 1291-5.
16. Pietrangelo A. Iron, oxidative stress and liver fibrogenesis. J Hepatol 1998; 28 (Suppl 1): 8-13.
17. Videla LA, Fernandez V, Tapia G, Varela P. Oxidative stress-mediated hepatotoxicity of iron and copper: Role of Kupffer cells. Biometals 2003; 16: 103-11.
18. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science 1987; 235: 1043-6.
19. Farrera JA, Jauma A, Ribo JM, et al. The antioxidant role of bile pigments evaluated by chemical tests. Bioorg Med Chem 1994; 2: 181-5.
20. Stocker R. Antioxidant activities of bile pigments. Antioxid Redox Signal 2004; 6: 841-9.
21. Edwards CQ, Cartwright GE, Skolnick MH, Amos DB. Homozygosity for hemochromatosis: Clinical manifestations. Ann Intern Med 1980; 93: 519-25.
22. Alizadeh BZ, Njajou OT, Houwing-Duistermaat JJ, et al. Does bilirubin protect against hemochromatosis gene (HFE) related mortality? Am J Med Genet A 2004; 129A: 39-43.
23. McCarty MF. "Iatrogenic Gilbert syndrome" - a strategy for reducing vascular and cancer risk by increasing plasma unconjugated bilirubin. Med Hypotheses 2007; 69: 974-94.
24. Tenhunen R, Marver HS, Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci USA 1968; 61: 748-55.
25. Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333: 1171-5.
26. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 1996; 347: 578-81.
27. Sugatani J, Yamakawa K, Yoshinari K, et al. Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. Biochem Biophys Res Commun 2002; 292: 492-7.
28. Maruo Y, D'Addario C, Mori A, et al. Two linked polymorphic mutations (A(TA)7TAA and T-3279G) of UGT1A1 as the principal cause of Gilbert syndrome. Hum Genet 2004; 115: 525-6.
29. Costa E, Vieira E, Dos SR. The polymorphism c.-3279T>G in the phenobarbital-responsive enhancer module of the bilirubin UDP-glucuronosyltransferase gene is associated with Gilbert syndrome. Clin Chem 2005; 51: 2204-6.
30. Sugatani J, Mizushima K, Osabe M, et al. Transcriptional regulation of human UGT1A1 gene expression through distal and proximal promoter motifs: Implication of defects in the UGT1A1 gene promoter. Naunyn Schmiedebergs Arch Pharmacol 2008; 377: 597-605.
31. Worwood M. Inherited iron loading: Genetic testing in diagnosis and management. Blood Rev 2005; 19: 69-88.
32. Scheuer PJ. Classification of chronic viral hepatitis: A need for reassessment. J Hepatol 1991; 13: 372-4.
33. Sikorska K, Stalke P, Jaskiewicz K, Romanowski T, Bielawski KP. Could iron deposits in hepatocytes serve as a prognostic marker of HFE gene mutations? Hepatogastroenterology 2008; 55: 1024-8.
34. Borlak J, Thum T, Landt O, Erb K, Hermann R. Molecular diagnosis of a familial nonhemolytic hyperbilirubinemia (Gilbert's syndrome) in healthy subjects. Hepatology 2000; 32: 792-5.
35. Bosma PJ. Inherited disorders of bilirubin metabolism. J Hepatol 2003; 38: 107-17.
36. Merryweather-Clarke AT, Pointon JJ, Jouanolle AM, Rochette J, Robson KJ. Geography of HFE C282Y and H63D mutations. Genet Test 2000; 4: 183-98.
37. Gilbert A, Lereboullet P. La cholémie simple familiale. Semaine Med 1901; 21: 241-3.
38. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 1998; 95: 8170-4.
39. Monaghan G, McLellan A, McGeehan A, et al. Gilbert's syndrome is a contributory factor in prolonged unconjugated hyperbilirubinemia of the newborn. J Pediatr 1999; 134: 441-6.
40. Premawardhena A, Fisher CA, Liu YT, et al. The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): Hematologic and evolutionary implications. Blood Cells Mol Dis 2003; 31: 98-101.
41. Shatalova EG, Walther SE, Favorova OO, Rebbeck TR, Blanchard RL. Genetic polymorphisms in human SULT1A1 and UGT1A1 genes associate with breast tumor characteristics: A case-series study. Breast Cancer Res 2005; 7: R909-21.
42. Nikolac N, Simundic AM, Topic E, et al. Rare TA repeats in promoter TATA box of the UDP glucuronosyltranferase (UGT1A1) gene in Croatian subjects. Clin Chem Lab Med 2008; 46: 174-8.
43. Sai K, Saeki M, Saito Y, et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 2004; 75: 501-15.
44. Saeki M, Saito Y, Jinno H, et al. Haplotype structures of the UGT1A gene complex in a Japanese population. Pharmacogenomics J 2006; 6: 63-75.
45. Yea SS, Lee SS, Kim WY, et al. Genetic variations and haplotypes of UDP-glucuronosyltransferase 1A locus in a Korean population. Ther Drug Monit 2008; 30: 23-34.
46. Raijmakers MT, Jansen PL, Steegers EA, Peters WH. Association of human liver bilirubin UDP-glucuronyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene. J Hepatol 2000; 33: 348-51.
47. Peters WH, te Morsche RH, Roelofs HM. Combined polymorphisms in UDP-glucuronosyltransferases 1A1 and 1A6: Implications for patients with Gilbert's syndrome. J Hepatol 2003; 38: 3-8.
48. Mercke OJ, Andrade J, Holmberg K, Hoglund P, Malmqvist U, Odeberg J. UGT1A polymorphisms in a Swedish cohort and a human diversity panel, and the relation to bilirubin plasma levels in males and females. Eur J Clin Pharmacol 2006; 62: 829-37.
49. Ostanek B, Furlan D, Mavec T, Lukac-Bajalo J. UGT1A1(TA)n promoter polymorphism - a new case of a (TA)8 allele in Caucasians. Blood Cells Mol Dis 2007; 38: 78-82.
50. Kaniwa N, Kurose K, Jinno H, et al. Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C>T (P229L) found in an African-American. Drug Metab Dispos 2005; 33: 458-65.
51. Girard H, Butler LM, Villeneuve L, et al. UGT1A1 and UGT1A9 functional variants, meat intake, and colon cancer, among Caucasians and African-Americans. Mutat Res 2008; 644: 56-63.
52. Pietrangelo A. Hemochromatosis 1998: Is one gene enough? J Hepatol 1998; 29: 502-9.
53. Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002; 110: 1037-44.
54. Bridle KR, Frazer DM, Wilkins SJ, et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet 2003; 361: 669-73.
55. Lee P, Peng H, Gelbart T, Wang L, Beutler E. Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci USA 2005; 102: 1906-10.
56. Fillet G, Beguin Y, Baldelli L. Model of reticuloendothelial iron metabolism in humans: Abnormal behavior in idiopathic hemochromatosis and in inflammation. Blood 1989; 74: 844-51.
57. Recalcati S, Pometta R, Levi S, Conte D, Cairo G. Response of monocyte iron regulatory protein activity to inflammation: Abnormal behavior in genetic hemochromatosis. Blood 1998; 91: 2565-72.
58. Fleming RE, Sly WS. Hepcidin: A putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease. Proc Natl Acad Sci USA 2001; 98: 8160-2.
59. Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC. Inappropriate expression of hepcidin is associated with iron refractory anemia: Implications for the anemia of chronic disease. Blood 2002; 100: 3776-81.
60. Novotny L, Vitek L. Inverse relationship between serum bilirubin and atherosclerosis in men: A meta-analysis of published studies. Exp Biol Med (Maywood) 2003; 228: 568-71.
61. Ching S, Ingram D, Hahnel R, Beilby J, Rossi E. Serum levels of micronutrients, antioxidants and total antioxidant status predict risk of breast cancer in a case control study. J Nutr 2002; 132: 303-6.